Cargando…
NT-proBNP and stem cell factor plasma concentrations are independently associated with cardiovascular outcomes in end-stage renal disease hemodialysis patients
AIMS: End-stage renal disease (ESRD) treated by chronic hemodialysis (HD) is associated with poor cardiovascular (CV) outcomes, with no available evidence-based therapeutics. A multiplexed proteomic approach may identify new pathophysiological pathways associated with CV outcomes, potentially action...
Autores principales: | Rossignol, P, Duarte, K, Bresso, E, A, Åsberg, Devignes, M D, Eriksson, N, Girerd, N, Glerup, R, Jardine, A G, Holdaas, H, Lamiral, Z, Leroy, C, Massy, Z, März, W, Krämer, B, Wu, P H, Schmieder, R, Soveri, I, Christensen, J H, Svensson, M, Zannad, F, Fellström, B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797490/ https://www.ncbi.nlm.nih.gov/pubmed/36600882 http://dx.doi.org/10.1093/ehjopen/oeac069 |
Ejemplares similares
-
Die Biomarker BNP und NT‑proBNP
por: Oremek, G. M., et al.
Publicado: (2023) -
Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial
por: Salib, Madonna, et al.
Publicado: (2021) -
Arteriovenous fistula thrombosis is associated with increased all-cause and cardiovascular mortality in haemodialysis patients from the AURORA trial
por: Girerd, Sophie, et al.
Publicado: (2019) -
Agreement of BNP and NT-proBNP and the influence of clinical and laboratory variables
por: Curiati, Milena Novaes Cardoso, et al.
Publicado: (2013) -
The Ability of Heart Failure Specialists to Accurately Predict NT-proBNP Levels Based on Clinical Assessment and a Previous NT-proBNP Measurement
por: Sedlak, Tara L, et al.
Publicado: (2008)